Department of Molecular Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
Received 7 February 2004/ Returned for modification 9 March 2004/ Accepted 10 June 2004
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Hepatitis B virus (HBV) X protein (HBx), a multifunctional viral regulator protein of HBV (13), directly interacts with RNA polymerase II subunit 5 (RPB5) and modulates activated transcription as a coactivator in vivo and in vitro (1). This observation suggested the notion that RPB5 is a communicating subunit of RNA polymerase II and that it interacts with transcriptional regulators (10, 11, 27). Consistent with this notion, a novel cellular protein, RPB5-mediating protein (RMP), was identified and selected by the far-Western cloning method (4). The specific binding of RMP and RPB5 requires the RPB5-binding region of RMP (amino acids [aa] 151 to 231) and the central part (or rather, the C terminus of the exposed domain) of RPB5, which overlaps with the HBx-binding region. RMP negatively modulates RNA polymerase II function in the absence of HBx and antagonizes the coactivator function of HBx by competitive binding to RPB5 (4, 11). RMP is composed of 508 aa residues. However, its cDNA might be reconstructed, since the 5' sequence covering the first 25 aa is not from the sequence at the locus of the gene in human chromosome 19, and probably during cloning using a 5' and 3' rapid amplification of cDNA ends method due to the template switching.
Recently, a novel aspect of RMP suggested that RPB5 and RMP/URI, (unconventional prefoldin RPB5 interactor) are involved in a mammalian TOR (target of rapamycin) kinase signaling pathway that coordinates the regulation of nutrient availability with gene expression by interacting with STAP1 (SKP2-associating
-class prefoldin 1) (5). A version of RMP truncated at the N-terminal 50 aa has been reported to be the cytoplasmic protein NNX3 (26). We examined the subcellular localization of RMP using green fluorescent protein (GFP) and other tagging methods. Here, we report that RMP is mainly localized in the cytoplasm, with weak and diffuse signals in the nucleus, and that two localization signals, a nuclear localization signal (NLS) and a cytoplasmic localization signal (CLS), are important for the subcellular localization of RMP. Also, we report on the RMP-interacting partner, DNA methyltransferase 1 (DNMT1)-associating protein (DMAP1), a putative corepressor, which facilitates the exclusive nuclear localization of RMP and augments its corepressor activity.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Yeast two-hybrid assays. Yeast transformation and two-hybrid screening were performed as previously described (6, 30). Briefly, Saccharomyces cerevisiae strain PJ69-4A (GAL7-LacZ GAL1-HIS3 GAL2-ADE2) was used for yeast two-hybrid screening. Gal4 activation domain-fused cDNAs from a pACT library of human lymphocytes were used. A plasmid expressing RMP fused to the Gal4 DNA-binding domain was prepared by inserting full-length RMP cDNA into the yeast expression vector pAS1. The transformants were screened for growth on plates lacking tryptophan, leucine, and histidine and supplemented with 40 mM 3-amino-1,2,4-triazole at 27°C for 3 to 6 days. Histidine-positive colonies were further screened by ß-galactosidase assays for positive interaction. Plasmids harboring cDNA were isolated from positive yeast colonies and transformed into Escherichia coli. The cDNAs of positive library plasmids were sequenced and compared to existing databases by using the BLAST algorithm.
Expression and purification of recombinant proteins. Glutathione S-transferase (GST)-fused and FLAG-tagged proteins were expressed and purified as previously described (1, 10). Briefly, transformed bacterial cells (BL21) were harvested by centrifugation and suspended in PBST buffer A {phosphate-buffered saline without CaCl2 and MgCl2 [PBS()] containing 0.5% Triton X and 1 mM dithiothreitol (DTT)}. After centrifugation of the sonicated lysate, the supernatant was passed through DEAE-Sepharose, and GST-fused proteins were recovered with glutathione-Sepharose 4B beads (Amersham Biosciences, Inc.), while FLAG-tagged proteins were bound to anti-FLAG M2 resin (Sigma). The resin was washed, and the GST-fused or FLAG-tagged proteins were then eluted with glutathione or FLAG peptide, respectively. The eluted solution was dialyzed against buffer containing 100 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 1 mM DTT.
Preparation of cell extracts, coimmunoprecipitation, and Western blot analysis. For in vivo immunoprecipitation assays, transfected COS1 cells were harvested and washed with PBS() and sonicated in lysis buffer (50 mM Tris-HCl [pH 7.4], 200 mM NaCl, 1 mM EDTA, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 10 mM leupeptin, 10mM aprotinin, and 1 mM DTT). For each test tube, the total lysate derived from 2.5 x 105 cells was diluted 10-fold with lysis buffer containing 1% bovine serum albumin (BSA) and precleared by incubation with protein A-Sepharose resin (Amersham Pharmacia) for 1 h at 4°C. The precleared lysate was incubated with 10 µl of anti-FLAG M2 affinity resin for 2 h at 4°C. The resin was preblocked in lysis buffer containing 1% BSA. After an extensive wash with lysis buffer containing 300 mM NaCl, the bound proteins were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred onto nitrocellulose membranes, and subjected to Western blot analysis with monoclonal anti-GST antibodies (Santa Cruz). For in vitro binding experiments, bacterially expressed and purified full-length FLAG-RMP or mammalian expressed and anti-FLAG M2 resin affinity-purified FLAG-RMP mutant proteins were mixed with bacterially expressed and affinity-purified GST-DMAP1. For one test tube, 200 ng of each purified protein was applied. The bound proteins were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred onto nitrocellulose membranes, and subjected to Western blot analysis with anti-GST or anti-FLAG M2 antibodies. The proteins were visualized by enhanced chemiluminescence according to the manufacturer's instructions (Amersham Pharmacia Biotech).
Cell culture and transient transfection. COS1 cells (a monkey kidney cell line), HepG2 cells, and HLE cells (a human hepatoma cell line) were cultured in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 5% fetal calf serum (CELLect R GOLD) and 20 mg of antibiotics (ampicillin and kanamycin; Meigi Co., Ltd.)/ml and maintained in an incubator with 5% CO2 at 37°C. The cells were transfected by standard CaCl2-mediated transfection.
Immunofluorescence and confocal microscopy. HLE cells grown on glass coverslips were washed once in PBS(), fixed with 2% formaldehyde in PBS() for 30 min at room temperature (RT), permeabilized for 5 min with 100% cold methanol, and then dried at 25°C. GFP-fused proteins were detected after being counterstained with 0.0005% Evans Blue. For immunostaining, coverslips were blocked in 1.5% BSA in PBS() at RT for 1 h and incubated with primary antibodies in a humidifying chamber at RT for 1 h (1:300 monoclonal anti-GST antibody). The cells were washed five times with PBS() and incubated at RT for 1 h with secondary antibodies (1:30 goat anti-mouse immunoglobulin G [IgG]-Texas Red; Southern Biotechnology Associates, Inc.). Subsequently, the cells were washed five times in PBS() and mounted using Vectashield mounting medium. Immunofluorescent images were acquired using a confocal laser scanning microscope (LSM510; Carl Zeiss Co., Ltd).
Luciferase assay. Approximately 105 HepG2 cells were plated in six-well tissue culture plates, and 1 day after being plated, they were cotransfected with plasmid cocktails. The total DNA concentration in the transfection cocktails was adjusted using plasmid pSG5UTPL. Forty-eight hours after transfection, luciferase and Renilla assays were performed using a Dual Luciferase Assay kit (Promega) according to the manufacturer's instructions. Luciferase activity was normalized against Renilla activity.
| RESULTS |
|---|
|
|
|---|
|
|
We examined the correlation between subcellular localization and the corepressor ability of RMP using these truncation mutants. GFP-RMP1-508 exhibited a corepressor activity similar to that of FLAG-RMP1-508 in the presence of Gal-VP16 with a luciferase reporter under the control of a Gal4 DNA-binding repeat acting as an enhancer (Fig. 2B, bars 9 to 16). On the other hand, RMP151-508 exhibited significantly higher repression activity than RMP1-508 did, while RMP1-231 containing an RPB5-binding region failed to repress transactivation by GAL-VP16. This result indicates that the corepressor activity might be localized in the C terminus, that the RPB5-binding region does not contribute much to the corepressor function in the presence of Gal-VP16, and that the RPB5-binding region itself has no effect on corepressor activity (Fig. 2B, bars 17 to 24).
The NLS at the C terminus and the CC domain as a CLS. Since GFP-RMP151-508 was exclusively localized in the nucleus (Fig. 2A, row c), the contribution of the putative NLS located between aa 339 and 343 was evaluated by amino acid deletion and substitution. GFP-RMP232-508 was exclusively localized in the nucleus, but GFP-RMP232-508dNLS was distributed in the cytoplasm and nucleus (Fig. 3A, rows a and b). When the NLS was replaced with alanines, the same results as for GFP-RMP232-508dNLS were observed (data not shown). This indicates that aa 339 to 343 function as an NLS, although apparently it does not contribute much to the subcellular localization of RMP.
|
|
40% of the clones possessed the common N-terminal portion of RMP itself. DMAP1 is a putative corepressor and an associating factor with DNMT1, which is involved in gene silencing (20, 21, 22). The interaction between DMAP1 and RMP was confirmed in yeast cells expressing RMP and DMAP1 in the presence of 40 mM 3-amino triazole (Fig. 5A). The specific interaction was also demonstrated in mammalian cells transiently coexpressing differently tagged proteins (Fig. 5B, lanes 2 and 4). Consistent with the results in vivo, RMP immunoprecipitated DMAP1, demonstrating direct binding between RMP and DMAP1 in vitro with partially purified GST-DMAP1 and FLAG-RMP proteins (Fig. 5D, lane 2). These results are consistent with specific and direct interaction between RMP and DMAP1.
|
Homotypic interaction of RMP. To confirm the homotypic interaction of RMP in mammalian cells, immunoprecipitation experiments were carried out with the lysates of COS1 cells transiently overexpressing FLAG-RMP and GST-RMP. The homotypic interaction of RMP demonstrated in vivo was consistent with the cloning results of the two-hybrid system (Fig. 6A). Homotypic interaction was demonstrated in vitro with partially purified FLAG-RMP and GST-RMP (Fig. 6B), indicating that the CC domain is responsible for the homotypic interaction of RMP in vivo and in vitro (Fig. 6).
|
|
| DISCUSSION |
|---|
|
|
|---|
RMP was isolated during the search to find transcriptional modulators that interact with RPB5 (4) to understand the transcriptional modulation mechanism of HBx. Since RMP exhibits corepressor activity in the absence of HBx and antagonizes the coactivator activity of HBx by competitive binding to RPB5, we designated it RPB5-mediating protein (RMP) (4). However, its cDNA is reconstructed probably during cloning using a 5' and 3' rapid amplification of cDNA ends method due to template switching, since the 5' sequence covering the first 25 aa is not from the sequence at the locus of the gene in human chromosome 19. RMP is distinct from the mediating protein families of the homoenzyme (15), and the molar ratio of RMP to RPB5 was <0.1 under normal growth conditions (unpublished data). The corepressor activity of RMP is rather weak, and cytoplasmic localization has been reported for a shorter isoform (aa 51 to 508). In this study, we report that RMP is mainly localized in the cytoplasm, accompanied by weak and diffuse nuclear localization. We describe the two elements, the NLS and the CC domain of RMP, that are important for subcellular localization. We isolated DMAP1, a putative interacting partner of RMP that facilitates the nuclear localization of RMP by interacting with the CC domain. DMAP1 is also a putative corepressor and associating factor of DNMT1, which is involved in gene silencing (20, 21, 22). DMAP1 augmented the corepressor activity of RMP, while DMAP1 had no effect on transcriptional activation driven by Gal-VP16 in the absence of RMP. The augmentation of the corepressor activity of RMP by DMAP1 might be due to efficient nuclear localization by DMAP1, but our preliminary results suggested that DMAP1 may play another role in transcriptional regulation, since it was recruited to the promoter by RMP (data not shown). The interaction of DMAP1 and RMP may facilitate the recruitment of DNMT1 in promoter regions that are important for the negative regulation of transcription by modifying chromatin structure. Such a possibility remains to be addressed. Homotypic interaction of RMP through the CC domain was also observed but did not affect the mostly cytoplasmic localization of RMP. Similar results were observed with RMP51-508 (or NNX3) (data not shown), the shorter isoform of RMP (26).
During the preparation of this study, Gstaiger et al. reported a cDNA encoding 534 aa, called URI, which overlaps aa 26 to 508 of RMP. Human URI comprises
-class prefoldin (PFD) in aa 1 to 154, the RPB5 interaction region, a long acidic sequence, and a short conserved C-terminal sequence, all of which are evolutionarily conserved among eukaryotes (reference 5 and its supplemental data). Their findings show that URI/RMP is a negative transcriptional regulator under the control of TOR kinase and that URI/RMP occurs as a complex with STAP1, which is a member of the
-class PFDs; two other low-molecular-weight ß-class PFDs; and RPB5. Interestingly, immunoaffinity purification using anti-STAP1 IgG allowed the recovery of not only URI/RMP, but also RPB5. However, the other RNA polymerase subunits seem not to be present (Fig. 1 of reference 5). The result strongly suggests multiple roles of RPB5 assembled in RNA polymerases and in complex with STAP1, implying a mechanism for regulating the dynamic distribution of RPB5 in the two complexes. The subcellular localization of the complex including URI/RMP and RPB5 remains unresolved. Yeast URI (Bud27p) has been documented as a cytoplasmic protein in the Saccharomyces Genome Database (SGD) (http://www.yeastgenome.org/). We demonstrated here that the RPB5-binding region does not contribute to the nuclear localization of RMP (Fig. 2A). Our preliminary confocal result using GFP-RPB5 showed that RPB5 is localized in the nucleus and cytoplasm and that the overexpression of RPB5 could not induce the nuclear localization of RMP (data not shown).
Since the RMP construct harbors a short stretch of the N-terminal CC, ß-sheet, and C-terminal CC regions of PFD, there is a possibility that RMP, a truncated form of the full-length URI, but not URI may interact with DMAP1. To address this possibility, the subcellular localization of human URI (kindly provided by M. Gstaiger and W. Krek) was addressed in the presence and absence of DMAP1. URI was mainly localized in the cytoplasm in the absence of coexpression of DMAP1, and URI interacted with GST-DMAP1 in vivo, changing the subcellular localization of URI from the cytoplasm to the nucleus (Fig. 8). Therefore, the present observations with RMP reflect the properties of URI, although with the difference that diffuse signals of URI, but not RMP, seem to remain in the cytoplasm in the presence of DMAP1. Taken together, our results show that RMP/URI is a distinct protein in the PDF family, since it has dual roles in the cytoplasm and the nucleus and its subcellular localization is regulated by interacting partners. The previously reported roles of RPB5 in activating transcription and transcriptional modulation by HBx may need to be reevaluated, considering the new role of RPB5 that is not assembled in RNA polymerases (10, 12).
|
| ACKNOWLEDGMENTS |
|---|
This work was supported in part by Grant-in-aid for Scientific Research category B no. 111480200 and Grant-in-aid for Scientific Research on Priority Areas Cancer, Mechanism of Oncogenesis and Anti-oncogenesis no. 12213050 from the Ministry of Education, Sports, Culture and Technology of Japan.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Chung, W.-H., J. L. Craighead, W.-H. Chang, C. Ezeokonkwo, A. Bareket-Samish, R. D. Kornberg, and F. J. Asturias. 2003. RNA polymerase II/TFIIF structure and conserved organization of the initiation complex. Mol. Cell 12:1003-1013.[CrossRef][Medline]
3. Cramer, P. D., A. Bushnell, J. Fu, A. L. Gnatt, B. Maier-Davis, N. E. Thompson, R. R. Burgess, A. M. Edwards, P. R. David, and R. D. Kornberg. 2000. Architecture of RNA polymerase II and implications for the transcription mechanism. Science 288:640-649.
4. Dorjsuren, D., Y. Lin, W. Wei, T. Yamashita, T. Nomura, N. Hayashi, and S. Murakami. 1998. RMP, a novel RNA polymerase II subunit 5-interacting protein, counteracts transactivation by hepatitis B virus X protein. Mol. Cell. Biol. 18:7546-7555.
5. Gstaiger, M., B. Luke, D. Hess, E. J. Oakeley, C. Wirbelauer, M. Blondel, M. Vigneron, M. Peter, and W. Krek. 2003. Control of nutrient-sensitive transcription programs by the unconventional prefoldin URI. Science 302:1208-1212.
6. James, P., J. Halladay, and E. A. Craig. 1996. Genomic libraries and a host strain designed for highly efficient two-hybrid selection in yeast. Genetics 144:1425-1436.[Abstract]
7. Kim, Y. J., S. Bjorklund, M. Li, H. Sayer, and R. D. Kornberg. 1994. A multiprotein complex mediator of transcriptional activation and its interaction with C-terminal domain of RNA polymerase II. Cell 77:599-608.[CrossRef][Medline]
8. Koleske, A. J., and R. A. Young. 1994. An RNA polymerase II holoenzyme responsive to activators. Nature 368:466-469.[CrossRef][Medline]
9. Lewis, B. A., and D. Reinberg. 2003. The mediator coactivator complex: functional and physical roles in transcriptional regulation. J. Cell Sci. 116:3667-3675.
10. Lin, Y., H. Tang, T. Nomura, D. Dorjsuren, N. Hayashi, W. Wei, T. Ohta, R. Roeder, and S. Murakami. 1998. The hepatitis B virus X protein is a co-activator of activated transcription that modulates the transcription machinery and distal binding activators. J. Biol. Chem. 273:27097-27103.
11. Lin, Y., T. Nomura, J. H. Cheong, D. Dorjsuren, K. Iida, and S. Murakami. 1997. Hepatitis B virus X protein is a transcriptional modulator that communicates with transcriptional factor IIB and RNA polymerase II subunit 5. J. Biol. Chem. 272:7132-7139.
12. Miyao, T., and N. A. Woychik. 1998. RNA polymerase subunit RPB5 plays a role in transcriptional activation. Proc. Natl. Acad. Sci. USA 95:15281-15286.
13. Murakami, S. 2001. Hepatitis B virus X protein: multifunctional viral regulator. J. Gastroenterol. 36:651-660.[CrossRef][Medline]
14. Murakami, S. 1999. Hepatitis B virus X protein: structure, function and biology. Intervirology 42:81-99.[CrossRef][Medline]
15. Naar, A. M., B. D. Lemon, and R. Tjian. 2001. Transcriptional coactivator complexes. Annu. Rev. Biochem. 70:475-501.[CrossRef][Medline]
16. Naar, A. M., D. J. Taatjes, W. Zhai, E. Nogales, and R. Tjian. 2002. Human CRSP interacts with RNA polymerase II CTD and adopts a specific CTD-bound conformation. Genes Dev. 16:1339-1344.
17. Orphanides, G., T. Lagrange, and D. Reinberg. 1996. The general transcription factors of RNA polymerase II. Genes Dev. 10:2657-2683.
18. Petermann, R., B. M. Mossier, D. N. Aryee, V. Khazak, E. A. Golemis, and H. Kovar. 1998. Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II. Oncogene 17:603-610.[CrossRef][Medline]
19. Pillai, B., V. Sampath, N. Sharma, and P. Sadhale. 2001. Rpb4, a non-essential subunit of core RNA polymerase II of Saccharomyces cerevisiae is important for activated transcription of a subset of genes. J. Biol. Chem. 276:30641-30647.
20. Robert, M. F., S. Morin, N. Beaulieu, F. Gauthier, I. C. Chute, A. Barsalou, and A. R. Macleod. 2003. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat. Genet. 33:61-65.[CrossRef][Medline]
21. Robertson, K. D., S. Ait-Si-Ali, T. Yokochi, P. A. Wade, P. L. Jones, and A. P. Wolffe. 2000. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet. 25:338-342.[CrossRef][Medline]
22. Rountree, M. R., K. E. Bachman, and S. B. Baylin. 2000. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet. 25:269-277.[CrossRef][Medline]
23. Schlegel, B. P., V. J. Green, J. A. Ladias, and J. D. Parvin. 2000. BRCA1 interaction with RNA polymerase II reveals a role for hRPB2 and hRPB10
in activated transcription. Proc. Natl. Acad. Sci. USA 97:3148-3153.
24. Sentenac, A. 1985. Eukaryotic RNA polymerases. Crit. Rev. Biochem. 18:31-91.[Medline]
25. Tan, Q., K. L. Linask, R. H. Ebright, and N. A. Woychik. 2000. Activation mutants in yeast RNA polymerase II subunit RPB3 provide evidence for a structurally conserved surface required for activation in eukaryotes and bacteria. Genes Dev. 14:339-348.
26. Van Leuven., F., S. Torrekens, D. Moechars, C. Hilliker, M. Buellens, M. Bollen, and J. Delabie. 1998. Molecular cloning of a gene on chromosome 19q12 coding for a novel intracellular protein: analysis of expression in human and mouse tissues and in human tumor cells, particularly Reed-Sternberg cells in Hodgkin disease. Genomics 54:511-520.[CrossRef][Medline]
27. Wei, W., D. Dorjsuren, Y. Lin, W. Qin, T. Nomura, N. Hayashi, and S. Murakami. 2001. Direct interaction between the subunit RAP30 of transcription factor IIF (TFIIF) and RNA polymerase subunit 5, which contributes to the association between TFIIF and RNA polymerase II. J. Biol. Chem. 276:12266-12273.
28. Woychik, N. A., and M. Hampsey. 2002. The RNA polymerase II machinery: structure illuminates function. Cell 108:453-463.[CrossRef][Medline]
29. Wu, S. Y., T. Zhou, and C.-M. Chiang. 2003. Human mediator enhances activator-facilitated recruitment of RNA polymerase II and promoter recognition by TATA-binding protein (TBP) independently of TBP-associated factors. Mol. Cell. Biol. 23:6229-6242.
30. Yokoyama, N., N. Hayashi, T. Seki, N. Pante, T. Ohba, K. Nishii, K. Kuma, T. Hayashida, T. Miyata, U. Aebi, M. Fukui, and T. Nishimoto. 1995. A giant nucleopore protein that binds Ran/TC4. Nature 376:184-188.[CrossRef][Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|